Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Primitive Neuroectodermal Tumor: early-phase trial registry

2 of 3 indexed Primitive Neuroectodermal Tumor trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Primitive Neuroectodermal Tumor: 3 US clinical trials tracked, 2 recruiting.

Primitive Neuroectodermal Tumor is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Seattle Children's Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition primitive-neuroectodermal-tumor

OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Primitive Neuroectoderma (th…67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Primitive Neuroectodermal Tumor

Primitive Neuroectodermal Tumor lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primitive Neuroectodermal Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primitive Neuroectodermal Tumor is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 13

Phase Distribution

PhaseTrial count
Phase 1 3

Named interventions

Most-linked intervention names on Primitive Neuroectodermal Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

HER2-specific chimeric antigen receptor (CAR) T cell Biological
1 trials
SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel Biological
1 trials
Zoledronate Drug
1 trials
TCRαβ+/CD19+ depleted Haploidentical HSCT Procedure
1 trials

US sites by state

Facility locations filed on Primitive Neuroectodermal Tumor trials. A trial with sites in several states counts in each.

Washington 2 trials
Wisconsin 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primitive Neuroectodermal Tumor page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primitive Neuroectodermal Tumor condition card totals 3 registered trials; most-linked intervention HER2-specific chimeric antigen receptor (CAR) T cell; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.